Key result
RAAS inhibition remains a foundational baseline treatment for HF, cardiorenal syndrome, and diabetic nephropathy.
This paper discusses the potential role of renin inhibition with Aliskiren in the prevention of atherosclerosis, beyond its established role in blood pressure reduction.
RAAS inhibition beyond BP effects may aid atherosclerosis; leaves open targeted trials for inflammation and remodeling.
The renin-angiotensin-aldosterone system (RAAS) regulates inflammation and vascular remodeling thus playing an important role in atherosclerosis, kidney disease and heart failure. As an example of this, the effector hormone Angiotensin II (AngII) was shown to promote oxidative stress, endothelial dysfunction and vascular inflammation [1], all of which would be detrimental. However, inhibiting the RAAS now goes beyond blood pressure reduction and is an important component of the baseline treatment of heart failure, cardiorenal syndrome and diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Kappel et al. (2014) conducted a review in Atherosclerosis, kidney disease, and heart failure. Aliskiren (renin inhibition) was evaluated. Inhibiting the renin-angiotensin-aldosterone system is an important component of the baseline treatment of heart failure, cardiorenal syndrome, and diabetic nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: